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Abstract 
Cellular damage and accumulation of extracellular matrix (ECM) protein in the glomerulo-
interstitial space are the signatures of chronic kidney disease (CKD). Hyperhomocysteinemia 
(HHcy), a high level of homocysteine (Hcy) is associated with CKD and further contributes to 
kidney damage. Despite large number of studies, the signalling mechanism of Hcy-mediated 
cellular damage and ECM remodelling in kidney remains inconclusive. Hey metabolizes to 
produce hydrogen sulphide (H2S), and a number of studies have shown that H2S mitigates 
adverse effect of HHcy in a variety of diseases involving several signalling molecules, 
including forkhead box O (FOXO) protein. FOXO is a group of transcription factor that 
include FOXO1, which plays important roles in cell growth and proliferation. On the other 
hand, a cell survival factor, Akt regulates FOXO under normal condition. However, the 
involvement of Akt/FOXO1 pathway in Hcy-induced mesangial cell damage remains elusive, 
and whether H2S plays any protective roles has yet to be clearly defined. We treated mouse 
mesangial cells with or without H2S donor, GYY4137 and FOXO1 inhibitor, AS1842856 in 
HHcy condition and determined the involvement of Akt/FOXO1 signalling cascades. Our 
results indicated that Hcy inactivated Akt and activated FOXO1 by dephosphorylating both 
the signalling molecules and induced FOXO1 nuclear translocation followed by activation of 
FOXO1 transcription factor. These led to the induction of cellular apoptosis and synthesis of 
excessive ECM protein, in part, due to increased ROS production, loss of mitochondrial 
membrane potential (m), reduction in intracellular ATP concentration, increased MMP-2, -
9, -14 mRNA and protein expression, and Col I, IV and fibronectin protein expression. 
Interestingly, GYY4137 or AS1842856 treatment prevented these changes by modulating 
Akt/FOXO1 axis in HHcy. We conclude that GYY4137 and / or AS1842856 mitigates HHcy 
induced mesangial cell damage and ECM remodelling by regulating Akt/FOXO1 pathway.  
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1. Introduction  
Hyperhomocysteinemia (HHcy), an increased plasma homocysteine (Hcy) level is prevalent 
among patients with chronic kidney diseases (CKD) [1]. The mesangial cell provides 
architectural support for glomerular capillary loops and are crucial players in the initiation 
and progression of many kidney diseases [2, 3].  Increased glomerular mesangial cell 
apoptosis / proliferation and excessive accumulation of extracellular matrix (ECM) protein 
leads to glomerulosclerosis in CKD patients [4, 5]; similar results are also reported in 
experimental CKD animals [6-8]. However, the precise cellular mechanisms of HHcy-
induced progressive glomerular damage, sclerosis and dysfunction remain elusive.  
 
PI3K/Akt/FOXO signalling pathway is an essential regulator of cell survival and apoptosis [9, 
10]. Akt, the serine/threonine kinase protein kinase B, was identified as a downstream 
component in survival signalling through phosphatidylinositol-3 kinase (PI3K). The Akt 
kinase is activated by phosphorylation at Thr308 and Ser473 mediated by 3-
phosphoinositide-dependent protein kinase 1 and 2, respectively [11, 12]. After 
phosphorylation at Thr308 and Ser473 position, activated Akt phosphorylates many 
substrates. The subgroup O of forkhead box (FOXO) transcription factors are major 
substrates for Akt. Akt phosphorylates FOXOs at three conserved serine/threonine residues 
(Thr24, Ser256, Ser319), facilitating their association with 14-3-3 chaperone and leading to 
nuclear export and transcriptional activation [13]. The FOXO family consists of four 
members, FOXO1, FOXO3, FOXO4 and FOXO6 that share a conserved forkhead DNA-
binding domain [14]. FOXOs therefore have emerged as an important effector arm of 
PI3K/Akt signalling by driving multiple cellular processes such as apoptosis, cell cycle, 
oxidative stress, DNA damage repair and glucose metabolism [15]. Recent reports illustrated 
that FOXO1 plays critical roles in cell cycle, proliferation, apoptosis, and tumorigenesis by 
regulating expression of its target genes [16]. Based on these previous reports, we 
hypothesize that FOXO1 may play a direct role in Hcy-induced mesangial cell apoptosis and 
ECM remodelling.   
 
Hcy-induced cell apoptosis has been studied in various cell types including neuronal [17], 
promyeloid [18], endothelial [19, 20], and mesangial cells [21].  The study in mesangial cells 
showed that Hcy induces apoptosis by activating p38-mitogen-activeated protein kinase [21]. 
Hcy was also shown to induce cell cycle arrest through PI3K/Akt/FOXO pathway in 
endothelial cells [22]. Our laboratory has previously reported that Hcy-induced apoptosis 
was mediated through generation of ROS that played a major role in ECM remodeling in 
HHcy-associated CKD [7]. Along the same line, our laboratory had previously demonstrated 
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mesangial cell death and ECM expansion that were directly linked to glomerulosclerosis [11, 
12], and H2S supplementation mitigated ECM remodeling [23, 24]. GYY4137, a H2S donor is 
now well-established compound that protect renal and cardiovascular fibrosis [25, 26]. The 
molecular signaling mechanism of these protections however has yet to be completely 
defined.   
 
In the present study, we aimed at delineating the role of Akt/FOXO signalling pathway in 
Hcy-mediated mesangial cell apoptosis and ECM accumulation. We also investigated 
whether and how H2S donor, GYY4137 modulates Akt/FOXO1 signalling pathway to mitigate 
Hcy-induced mesangial cell death and ECM remodeling.  
 
2. Materials and methods 
2.1. Antibodies and Reagents  
Primary antibodies against phospho-Akt (Cell Signaling, 9271); total Akt (44-609G), 
phospho-FOXO1 (PA5-37577), total FOXO1 (MA5-17078), MMP-2 (PA1-16667); MMP-9 
(MA5-15886) were from Thermo Fisher Scientific (Waltham, MA). MMP-14 (ab53712), 
Fibronectin (ab2413), ATP assay kit (ab83355), and FOXO1 transcription factor assay kit 
(ab207204) were purchased from Abcam (Cambridge, UK). Collagen-I (NBP1-30054) and 
Collagen-IV (NBP1-26549) were from Novus Biologicals (Centennial, CO). Cleaved 
caspase-3 (mAb9664) and cleaved caspase-7 (mAb8438) were from Cell Signaling 
(Danvers, MA). The -actin (sc81178), and HRP conjugated secondary antibodies that we 
used for immune-detection were from Santa Cruz Biotechnology (Dallas, TX).  GYY4137 
and L-Homocysteine, N-acetyl cysteine (NAC) was from Sigma-Aldrich, St. Louis, MO; and 
AS1842856 was from EMD Millipore, Burlington, MA. MK2206 was from Selleckchem, 
Houston, TX ; PVDF membrane was from Bio-Rad (Hercules, CA) and dihydroethidium 
(DHE) was from Invitrogen (Carlsbad, CA). JC-1 dye and Caspase3/7 green detection 
reagents were purchased from Thermo Fisher Scientific, Waltham, MA. Tunnel, and all other 
analytical reagents were from Sigma-Aldrich (St. Louis, MO) or available highest grade. 
Epiquik nuclear extraction kit (OP-0002-1), Direct-zol RNA miniprep (R2050S) were from 
Epigentek (Farmingdale, NY). EasyScript cDNA synthesis kit (G234) was from Midsci (Valley 
Park, MO), and GoTaq Hot start green mastermix (M512B) was from Promega (Madison, 
WI). 
  
2.2. Cell cultures and treatments  
Mouse SV40 MES 13 (murine mesangial) cells were obtained from the American Type 
Culture Collection (Rockville, MD). Cells were cultured and maintained in a complete DMEM 
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/ F12 medium (3:1) at 37 °C with 5% CO2, and were seeded onto 6-well culture plates at an 
equal density. At 80% confluence, cells were treated with Hcy (50 µM), GYY4137 (250 μM) 
and AS1842856 (0.1 µM) alone or with combination. Inhibitors were added 1 h prior to Hcy 
treatment. Cells were treated for 30 min for activation assay and 24 h for all other 
experiments. 
 
2.3. Assessment of cell apoptosis 
2.3.1. AnnexinV / PI assay:       
An Annexin V-FITC early apoptosis detection kit (Cell Signalling Technology, Inc; Danvers, 
MA) was used to identify the apoptotic cells within a cell population. Briefly, the cells were 
treated for 24 h and then trypsinized and collected by centrifugation, washed thrice with ice-
cold PBS and re-suspended at 105 cells/ml with 1X Annexin V Binding Buffer. Then, 1 μl of 
Annexin V-FITC conjugate and 12.5 μl of Propidium Iodide (PI) solution were added to each 
cell suspension (96 μl) and incubated 15 min on ice in the dark. Next, the cell suspension 
was diluted to a final volume of 250 μl/assay with ice cold 1X Annexin V Binding Buffer, and 
analysed immediately using a FACS (Accuri C6 plus Flow Cytometer, BD Bioscience).  
 
2.3.2 TUNEL assay:   
The terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labelling (TUNEL) 
assay was performed to detect mesangial cell apoptosis using in situ cell death detection kit, 
Fluorescein following the manufacturer's instructions (Roche, Sigma Aldrich). Mesangial 
cells were seeded onto chambered slide, and maintained in complete DMEM and treated 
with Hcy with or without GYY4137 and AS1842856 for 24 h. Cells were fixed with fixation 
solution for 20 min at room temperature, washed twice with PBS, then permeabilized with 
permeabilization solution for 5 min on ice. Cells were then washed twice with PBS. Fixed 
cells were incubated with 50 µl TUNEL reaction mixture for 60 min at room temperature, 
washed twice with PBS, and fluorescence microscopic analyses were performed.  
 
2.4. Detection of reactive oxygen species (ROS)   
ROS was detected in mesangial cells using Dihydroethidium (DHE) staining method as 
described previously [7]. Briefly, cells were fixed in 4% paraformaldehyde for 10 min, air-
dried and then washed with ice cold PBS. Cells were then incubated with DHE (0.5 μM) in a 
dark humidified chamber for 10 min at 37ºC. Cells were washed twice with PBS and were 
mounted with FluoroGel mounting medium (GeneTex Inc., Irvine, CA). Images were taken 
by laser scanning confocal microscope (Olympus FluoView 1000, Pittsburgh, PA) and 
analyzed using ImageJ software (NIH).  
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2.5. Assessment of mitochondrial membrane potential (ΔѰm) 
To assess the loss of m, fluoroprobe 5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazol-carbocyanine iodide (JC-1 dye) was used. Briefly, cells were 
exposed to Hcy with or without GYY4137 and AS1842856 for 24 h.  After treatment, cells 
were washed with PBS followed by staining with 2 µg/ml of JC-1 dye for 15 min in dark at 
37°C. Cells were then washed thoroughly with PBS, and imaged in confocal microscope 
(Olympus FluoView1000, Pittsburgh, PA). At a lower ΔѰm, JC-1 exists as a monomer and 
is visible in the green fluorescence channel. At a higher ΔѰm, JC-1 accumulates in the 
mitochondrial matrix and is visible in the red channel. Therefore, a decrease in ΔѰm could 
be detected by the transition from red to green fluorescence.  
 
2.6. ATP concentration measurement 
The ATP levels were measured using an ATP Colorimetric/Fluorometric Assay Kit (Abcam 
83355), according to the manufacturer's instructions. The absorbance was recorded by 
spectrophotometer at OD 570 nm. 
 
 
2.7. Detection of Caspase 3/7 activity 
After treatment, cells were labelled with 5 μM CellEvent™ caspase-3/7 green detection 
reagent in complete medium for 30 min at 37°C in the dark. Stained cells were washed twice 
with PBS, mounted with DAPI mounting medium, and observed under fluorescence 
microscope. Apoptotic cells with activated caspase-3/7 show bright green nuclei, while cells 
without activated caspase-3/7 exhibit minimal fluorescence signal.  
 
2.8. RNA extraction and semi-quantitative reverse transcription-PCR (RT-PCR) 
RNA was extracted from cells by using Direct-zol RNA miniprep kit. The quality of total RNA 
was measured by NanoDrop ND-1000 and only high quality RNA (260/280-2.00 and 
260/230-1.80) was used for reverse transcriptase PCR. The total RNA (2 μg) was reverse 
transcribed by using Easyscript cDNA synthesis kit according to the manufacturer’s 
instructions. PCR program for amplification of cDNA was performed using GoTaq Hot start 
green mastermix (Promega) according to manufacturer’s guidelines. The primer sequences 
and their accession / reference numbers are listed in Table 1.  
 
2.9. Western blot analysis 
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Protein was extracted from cells using RIPA buffer (Boston BioProducts, Worcester, MA), 
containing 1 mM phenylmethanesulfonyl fluoride (PMSF), and 1% protease inhibitor cocktail 
(Sigma-Aldrich, Saint Louis, MO). After sonication, protein lysate was centrifuged at 12,000 
g for 10 min at 4 ºC. Protein concentration was measured by Bradford assay. Equal amount 
of protein extract (25 µg) was electrophoretically separated by SDS-PAGE and 
immunoblotted onto PVDF membrane. The membranes were blocked with 5% non-fat milk 
for 60 min at room temperature and subsequently incubated with respective primary 
antibodies for overnight at 4 ºC. Membranes were washed three times with PBS followed by 
2 h incubation with respective secondary antibodies at room temperature. The membranes 
were washed to remove unbound secondary antibodies, and protein bands were visualized 
using ECL Luminata Forte (Millipore, Temecule, CA) in a Bio-Rad ChemiDoc system. Band 
intensity was quantified using ImageJ software.  
 
2.10. Immunofluorescence 
Cells were fixed in 4% paraformaldehyde for 10 min and washed thrice with ice cold PBS. 
Cells were then permeabilized with 0.25% Tween 20 in PBS for 10 min, and washed thrice 
with PBST (0.1% Tween 20). Cells were incubated in blocking buffer (1% BSA in PBST) for 
1 h, washed and then primary antibody (1:1000) was added and incubated at 4°C for 
overnight with gentle shaking. Secondary antibodies labeled with Alexa Fluor (Invitrogen) 
appropriate to the primary antibody species were applied to the cells for immunodetection. 
After washing with PBST cells were immediately visualized under a laser scanning confocal 
microscope (Olympus FluoView1000, Pittsburgh, PA) and images were captured using 
appropriate filters. Images were further analyzed for fluorescence intensity using ImageJ 
software.  
 
2.11. FOXO1 transcription factor activity assay 
Cell nuclear extracts were obtained from mesangial cells by using Epiquik nuclear extraction 
kit (OP-0002-1). FOXO1 transcription factor activity assay was performed by using ELISA kit 
(ab207204) according to manufacturers’ instruction. The absorbance was recorded by 
spectrophotometer at OD 450 nm. 
 
2.12. Statistical Analysis 
ImageJ software was used to calculate the mean values of protein expression. Data was 
expressed as mean ± SEM, n = 8-9 independent experiments as stated in the figure 
legends. The significance difference was determined by one-way ANOVA within and across 
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different effectors or inhibitors for repeated measures using GraphPad Prism. The 
significance was accepted at the level of p < 0.05.  
 
3. Results: 
3.1. Hcy-induced Akt / FOXO1 signalling was prevented by GYY and AS  
Hcy treatment decreased phosphorylation of Akt and FOXO1 in mesangial cells as 
measured by Western blot (Fig. 1A, B). Hcy treatment deactivated Akt by inhibiting 
phosphorylation of Akt, which in turn dephosphorylated FOXO1. After dephosphorylation, 
FOXO1 becomes transcriptionally active and translocates into the nucleus to activate its 
target genes [13]. Results of our study showed that Hcy-induced activation of FOXO1 was 
reversed by GYY treatment. A selective inhibitor FOXO1, AS which blocks transcription 
activity of FOXO1 [27], also suppressed Hcy-induced dephosphorylation and activation of 
FOXO1 in mesangial cells. We also measured whether Hcy induced nuclear translocation of 
FOXO1 because of its activation. Our results indicated that phosphorylated FOXO1 / total 
FOXO1 (pFOXO1 / tFOXO1) ratio in Hcy treated cells was significantly lower in nuclear 
fraction and higher in cytosolic fraction compared to their respective controls (Fig. 1C,D). 
These results indicated nuclear translocation of FOXO1 following Hcy-induced FOXO1 
activation. Interestingly, GYY or AS treatment prevented nuclear translocation of FOXO1 in 
Hcy-treated cells (Fig. 1C,D). No significant changes in terms of FOXO1 nuclear 
translocation was measured in cells treated with either GYY or AS alone (Fig. 1C,D). 
Additionally, we also measured FOXO1 activity following Hcy treatment with or without GYY, 
or AS. Corroborating with the immunoblotting results, activity assay demonstrated 
upregulated FOXO1 activity following Hcy treatment, which was mitigated and normalized by 
GYY or AS treatment (Fig. 1E). No significant changes were observed in cells treated with 
GYY or AS alone compared to control (Fig.1E).   
 
3.2. GYY and AS mitigated Hcy-induced MMPs induction and ECM protein expression  
MMPs are involved in ECM degradation, and therefore cause tissue remodelling in various 
physiological conditions [7, 28]. Hcy stimulates MMPs, in part, by oxidative activation and 
thus contributes to tissue remodelling [7]. On the contrary, Hcy also oxidatively modifies 
ECM proteins that MMPs cannot degrade, and therefore causes fibrosis [29]. Our results 
indicated that Hcy increased MMP-2, -9, and -14 mRNA (Fig. 2A) and protein (Fig. 2B) 
expression in mesangial cells compared to control cells, which were normalised by GYY 
treatment. Furthermore, Hcy induced increased MMP -2, -9, -14 mRNA and protein 
expression was also normalized by FOXO1 inhibitor AS, suggesting the involvement of 
FOXO1 signalling in regulating these above MMPs, both at the mRNA and the protein levels. 
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In drug control cells, i.e. in cells that were treated with GYY or AS alone, none of these 
above three MMPs gene or protein expression was significantly changed compared to 
negative controls (Fig. 2A,B).  
 
We also investigated the effect of GYY on Hcy-induced altered expression of ECM proteins 
Collagen I (Col I), Collagen IV (Col IV) and fibronectin (Fbn-1) and the results are shown in 
Fig. 3. Hcy induced the expression of Col I, Col IV and Fbn-1 in mesangial cells as 
measured by Western blotting. Interestingly, GYY or AS treatment mitigated the expression 
of these proteins in HHcy (Fig. 3). GYY or AS alone had no effect in the expression of these 
above ECM proteins in control cells, i.e., without Hcy treatment (Fig. 3).  
 
Further studies with immunofluorescence labelling confirmed that Hcy induced increased 
expression of MMP-14 and Col IV (Fig. 4A) and Fbn-1 (Fig. 4B) in mesangial cells was also 
attenuated by GYY or AS.    
 
3.3. Hcy-induced apoptosis was mitigated by GYY and AS via Akt / FOXO1 pathway 
We determined Hcy-induced mesangial cell apoptosis by Annexin V/PI staining and TUNEL 
assay. Flow cytometry assay indicated that Hcy significantly increased apoptotic cell death 
compared to control (Fig. 5A, B). This increase was attenuated by GYY treatment. To 
determine whether Akt / FOXO1 signalling pathway was involved in Hcy-induced cell death, 
we treated mesangial cells with Akt inhibitor, MK2206 (MK) and FOXO1 inhibitor, 
AS1842856 (AS). Our results indicated that blocking of FOXO1 by AS diminished Hcy-
mediated cell apoptosis, whereas Akt inhibition by MK2206 triggered Hcy-induced cell death 
(Fig. 5A,B). These flow cytometry findings were further supported by similar experiments 
with TUNEL staining (Fig. 5C); whereas GYY, MK or AS alone did not have effect on cell 
apoptosis as measured by flow cytometry or TUNEL assay. Together, these results suggest 
that Hcy inhibits Akt and activates FOXO1 to promote mesangial cell apoptosis, which can 
be attenuated by H2S treatment (Fig. 5A-C).    
 
3.4. GYY and AS prevented Hcy-induced Caspase-3/7 activation  
Loss of m triggers caspase activation, which is a characteristic and stereotyped feature of 
cell undergoing apoptosis. Further investigation of Hcy-induced mesangial cell apoptosis, as 
we have measured in our experiments reported in fig. 5A, B and C, we performed caspase-
3/7 activity assay in experimental and control cells. Results showed that mesangial cells 
treated with Hcy manifested increased caspase-3/7 activity compared to control (Fig. 6A). 
Interestingly, this increase activity was prevented cither by GYY or AS treatment along with 
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Hcy. GYY or AS lone did not affect caspase-3/7 basal activity (Fig. 6A). Further analyses of 
caspases-3/7 by Western blotting indicated upregulation of cleaved caspases-3/7 expression 
by Hcy in mesangial cells, which were normalized by GYY or AS treatment (Fig 6B). Similar 
to immunostaining results neither GYY nor AS alone affected cleaved caspase-3/7 
expression in these cells. These results further support our observation of Hcy-induced 
apoptosis (Fig. 5), and indicate that the apoptosis is in part by activation of caspase-3/7 
(Fig. 6A,B).  
 
3.5. GYY and AS mitigated Hcy-induced ROS production  
ROS production in mesangial cells was measured using oxidative florescent dye DHE, 
where red fluorescence indicates ROS production. Hcy robustly and significantly increased 
ROS production in mesangial cells compared to control cells (Fig. 7A,B). Interestingly, GYY 
or AS treatment significantly diminished DHE florescence indicating prevention of ROS 
production in Hcy treated cells. No apparent change on basal ROS production was observed 
in GYY or AS alone treated cells (Fig. 7A,B).  
 
3.6. Inhibition of ROS by NAC mitigated Hcy-induced MMPs and matrix protein 
induction  
To determine whether Hcy-induced ROS induces MMPs and ECM proteins, we pre-treated 
mesangial cells with N-acetyl cysteine (NAC), and then treated with Hcy. Results indicated 
that Hcy increased MMP-2, -9, and -14 protein expression in cells, which were normalised by 
NAC pre-treatment (Fig. 8A). The expression of these MMPs were at the baseline levels and 
remained unchanged in control groups with or without NAC. Similar to MMPs expression, 
matrix protein Col 1, Col IV and Fbn were upregulated in Hcy treated groups (Fig. 8B). 
Interestingly, upregulation of these matrix proteins were mitigated by NAC treatment. 
Virtually no differences were observed in immunoblots in the control groups treated with or 
without NAC (Fig. 8B).  
 
3.7. GYY and AS mitigated Hcy-induced mitochondrial dysfunction 
Excess ROS generation can lead to mitochondrial dysfunction resulting in lower 
mitochondrial membrane potential (m). Loss of m is an important factor for the 
induction of cell apoptosis [27]. We measured the change of m in mesangial cells 
exposed to Hcy. Our results indicated that Hcy treatment significantly decreased the red 
signal intensity while increasing the green signal intensity compared to control, which is 
indicative of collapsed ΔѰm (Fig. 9A,B). On the other hand, GYY treatment preserved 
increased red signal and decreased green signal intensity in Hcy treated cells indicating 
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normalization of ΔѰm. A similar result was observed following AS treatment in Hcy treated 
cells (Fig. 9A,B). Although a non-significant change in red/green color ratio in GYY treated 
control cells was observed, in AS alone treated cells a significant reduction of m, as 
measured by red/green ratio, was observed compared to control. However, this change 
was comparable to GYY alone (Fig. 9A,B). To further determine whether Hcy-induced loss 
of m has any effect on intracellular ATP production in mesangial cells, we measured 
intracellular ATP concentration by using assay kit as described in the materials and 
methods. Our result indicated that Hcy decreased intracellular ATP concentration about 
50% in mesangial cells (Fig. 9C). This decreased intracellular ATP concentration was 
restored by GYY or AS treatment in Hcy treated cells. No effects of GYY or AS alone on 
intracellular ATP concentration was observed (Fig. 9C). These results suggest that GYY 
and/or AS prevents Hcy-induced mitochondrial dysfunction by preserving ΔѰm and 
intracellular ATP concentration.   
 
4. Discussion 
Hyperhomocysteinemia (HHcy) is associated with chronic kidney disease (CKD) and 
increased plasma Hcy levels are linked to renal fibrosis [30-32]. Excessive accumulation of 
extracellular matrix (ECM) protein and upregulation of matrix metalloproteinases (MMPs) are 
major contributing factors leading to Hcy-mediated renal fibrosis and kidney dysfunction. 
Previously our laboratory has established that H2S supplementation is an effective treatment 
strategy to protect kidney from HHcy associated malfunctioning [6, 7]. Recent findings from 
our laboratory also demonstrated that GYY4137 (GYY), a H2S donor alleviated hypertensive 
kidney dysfunction and collagen realignment in diabetic kidney [24, 33]. Studies from other 
laboratories have further confirmed that GYY ameliorates cardiac and other vascular 
damages [31, 34]. Until now and to our best knowledge, no report is available suggesting 
specific signalling mechanism of protective effect of GYY in HHcy-associated cellular 
damage in kidney. Our present report bridges this knowledge gap, and highlights the 
important signalling mechanism suggesting the protective role of GYY on mouse mesangial 
cells in HHcy. In fig. 10, we schematically present our findings from this study for an easy 
comprehension.   
 
Results from the present study demonstrates that Hcy inhibited Akt activation and promoted 
FOXO1 activation by diminishing phosphorylation of both these signalling molecules. 
Deactivation and activation of Akt and FOXO1, respectively caused by dephosphorylation of 
these signalling molecules that led to cellular apoptosis and upregulation of MMP-2, -9, -14 
gene and protein expression contributing to increased ECM protein synthesis including 
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collagen and fibrinogen, causing mesangial ECM remodelling. We also provided evidence 
that Hcy-induced mesangial cell apoptosis was associated with excess ROS production, 
mitochondrial membrane depolarization and caspase activation.  These detrimental changes 
in HHcy were mitigated either by GYY or AS treatment that modulated Akt/FOXO1 signalling 
axis, where Akt appeared to be the upstream signalling of FOXO1. In fig. 10, we proposed 
the most possible mechanistic model based on our overall findings depicting how GYY 
and/or AS protects mesangial cells from apoptotic remodelling by regulating Akt / FOXO1 
signalling pathway in HHcy condition.  
 
Previous report suggests an interaction between membrane type-1 matrix metalloproteinase 
(MT1-MMP; MMP-14) and Akt kinase that induced endothelial cellular apoptosis [35]. 
Similarly, FOXO1 is also reported to be involved in promoting apoptosis in mitochondria-
dependent and - independent manner [36]. In addition, reports are available that the axis of 
Akt/FOXO1 regulated a number of cellular events including hepatic regeneration [37], 
osteoblast differentiation [38], cellular proliferation and cell death [39], and cardiac tissue 
remodelling [40]. Although, Akt/FOXO1-dependent regulation of H2S generation has been 
reported in endothelial dysfunction in portal hypertension [41], the reverse mechanism, i.e. 
whether H2S regulates Akt/FOXO1 is not well known. In our first set of experiment, we 
detected a significant lower level of pAkt and pFOXO1 protein expression in Hcy treated 
mesangial cells, which was reversed by H2S donor, GYY. GYY activated Akt, a cell survival 
factor, which further downregulated FOXO1 activation and protected cells from Hcy threat 
(Fig. 1). This result further supports the previous finding that FOXO1 is the downstream of 
Akt signalling [15], and that Akt/FOXO1 is involved in cellular apoptosis in HHcy.  
 
Extracellular matrix (ECM) turnover is one of the major pathological factors contributing to 
HHcy-associated renal fibrosis that leads to progressive decline of renal function in CKD [31, 
32]. Previously our laboratory showed that ROS plays an important role in Hcy-induced ECM 
remodelling in glomerulus by regulating the MMPs activity and collagen deposition [7]. Both 
ECM synthesis and degradation are maintained by MMPs, and changes in MMPs 
expression and activity can lead to ECM accumulation. In the present study, we detected 
Hcy-mediated significant increase in MMP-2, -9, and -14 mRNA and protein expression in 
mesangial cells, which were normalized by GYY treatment (Fig. 2). FOXO1 inhibitor, AS 
treatment also diminished Hcy-mediated overexpression of MMP-2, -9 and -14. We also 
observed Hcy induced collagen I (Col 1), collagen IV (Col IV) and fibronectin-1 (Fbn-1) 
protein expression in mesangial cells, which was normalized by GYY treatment (Fig. 3). 
FOXO1 inhibition also normalized Hcy-induced overexpression of Col I, Col IV and Fbn-1 in 
mesangial cells (Figs. 3, 4). These results reveal that GYY or AS treatment mitigates excess 
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ECM synthesis and accumulation in mesangial cells by modulating Akt/FOXO1 signalling 
cascade in HHcy. It is noteworthy to mention that we detected MMP-14, Col IV and Fbn1 
expression in mesangial cells by immunofluorescence (Fig. 4). The results indicated that 
they are localized mostly to the cytoplasm. We did not measure whether they are secreted 
into the extracellular fluid / culture medium. This important question of cellular biology 
remained unanswered in our study, which may occur in response to Hcy stress. Only future 
study can reveal whether Hcy-induction leads to ECM protein secretion from mesangial cells 
into the extracellular fluid, and whether GYY or AS can modulate their section, if any in 
HHcy. 
 
Recently, Hcy has been reported to induce endothelial cell apoptosis by modulating 
mitochondrial-dependent Akt pathway [42]. In addition, H2S has also been shown to reduce 
Hcy-induced neuronal cell death [43]. In our present study, we observed that Hcy promoted 
mesangial cell apoptosis, which was mitigated by treatment with H2S donor, GYY (Fig. 5). 
To further verify whether Hcy effect was through Akt, we treated cells with Akt inhibitor 
MK2206 (MK) with or without Hcy. Our results indicated that increase number of cellular 
apoptosis was measured in cells treated with Hcy plus MK, compared to Hcy or MK alone 
(Fig. 5). These results confirmed that Hcy induced Akt inactivation led mesangial cell death. 
On the other hand, this result was in contrast to healthy cells, where Akt inhibited FOXO1 
activation and protected cells from apoptosis. To verify involvement of FOXO1, we treated 
cells with FOXO1 inhibitor AS, and results indicated significant attenuation of Hcy-induced 
cellular apoptosis (Fig. 5). These results suggest a probable regulatory role of Akt / FOXO1 
signalling in GYY-mediated recovery of cellular damage in HHcy condition.  
 
Studies have reported that apoptotic cell death in renal mesangial cells occurred due to 
enhanced mitochondrial oxidative stress leading to mitochondrial membrane depolarization 
and followed by caspase activities [44, 45] . The association between excessive production 
of intracellular reactive oxygen species (ROS) and Hcy-induced renal damage is already 
been an established fact [7, 21]. However, the connection between caspase and oxidative 
stress in Hcy-induced mesangial cell death is not clear in the literature. Our results 
demonstrated Hcy induced caspase-3/7 expression and ROS production in mesangial cells 
(Fig. 6 and 7, respectively). Further studies revealed that treatment with a H2S donor, GYY 
or FOXO1 inhibitor, AS diminished caspase-3/7 overexpression and reduced ROS 
production in mesangial cells. These findings suggest the involvement and the regulation of 
FOXO1 pathway by H2S, which mitigates Hey-induced oxidative stress and caspase 
activation, and thus diminishes cellular apoptosis.   
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We and others have shown that Hcy induces oxidative stress, which in turn induces MMPs in 
a variety of pathological conditions, both in vivo and in vitro settings [32, 46, 47]. Changes in 
MMPs expression and activity can lead to disproportional ECM synthesis and accumulation 
causing deleterious vascular remodelling [48, 49]. Normal human kidney expresses MMP-2 
and -9 at a very low level [50], however during progressive renal fibrosis, the mRNA 
transcription and protein expression of MMP-2 and -9 were shown to be upregulated in 
human and rodent’s kidney [51-53]. In addition, overexpressed MMP-14 mRNA was also 
reported predominantly in cyst-lining epithelia in experimental polycystic kidney disease, and 
MMP inhibitor therapy decreased cyst formation [54]. It is important to mention that MMP-2 
and -9 are collagenases, and studies have shown renoprotective effects of these MMPs 
through promoting matrix turnover, and thus preventing ECM accumulation [55, 56]. On the 
contrary, elevated expressions and activities of MMP-2 and -9 have been observed in the 
fibrotic renal cortex suggesting their role in matrix accumulation associated with progressive 
renal scarring [57]. The mechanism of these paradoxical roles of MMPs are mostly 
unexplained in the literature. A possible explanation is that, in addition to collagen 
degradation, MMP-2 and -9 also degrade elastin [58]. And because the turnover of collagen 
is faster than elastin [59], oxidatively modified collagen is deposited faster than elastin or any 
other ultra-structural matrix proteins in an increased oxidant environment [29]. This causes 
ECM accumulation in certain disease conditions, such as in HHcy, where MMPs expression 
and activity is upregulated favouring fibrosis development.   
 
To determine whether Hcy-induced oxidative stress causes MMP-2, -9 and -14 dysregulation 
and ECM protein overexpression, and whether scavenging ROS by NAC in HHcy normalizes 
these MMPs expression and thus ECM protein, we threated mesangial cells with or with 
NAC along with Hcy. Our results indicated that Hcy mediated significant increase of MMP-2, 
-9, and -14 protein expression in mesangial cells, which was normalized by NAC treatment 
(Fig. 8).  We also observed Hcy-induced collagen I (Col 1), collagen IV (Col IV) and 
fibronectin-1 (Fbn-1) protein overexpression in mesangial cells was normalized by NAC 
treatment (Fig. 8). These results suggest that Hcy-induces ROS, and prevention of ROS 
production by NAC mitigates MMPs and ECM protein overexpression in mesangial cells. 
These findings are also in corroboration with our results that GYY mitigates MMPs and ECM 
protein expression through reducing ROS production (Figs. 2-4, and 7, respectively).  
 
Several studies have shown mitochondrial membrane depolarization is directly linked to 
excess ROS associated cellular damage [38]. To investigate the direct effect of Hcy-
mediated ROS production in mesangial cells, we measured mitochondrial membrane 
potential (m) and intracellular ATP concentration. The membrane-permeant JC-1 dye has 
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widely been used as an indicator of m. The dye exhibits potential-dependent 
accumulation in mitochondria, which is indicative of a shift of fluorescence emission from 
green to red. Thus, a decrease in the red/green fluorescence intensity ratio indicates 
mitochondrial depolarization. Our results indicated Hcy treatment caused a loss of 
mitochondrial membrane polarization as well as reduced ATP concentration in mesangial 
cells (Fig. 9), suggesting mitochondrial depolarization and ATP reduction. Interestingly, GYY 
treatment prevented depolarization and reserved ATP concentration. Similarly, FOXO1 
inhibitor AS also prevented Hcy-induced loss of m and reserved ATP concentration (Fig. 
9). These results suggest that Hcy-induced loss of m was through reduction of H2S and 
FOXO1 pathway.  
 
In conclusion, our study demonstrates that H2S donor, GYY mitigates HHcy associated 
mesangial cell death by attenuating excessive ROS production, ameliorating loss of 
mitochondrial membrane potential (m), preserving intracellular ATP concentration and 
by reducing caspase activation, which otherwise lead to collagen and fibrinogen synthesis 
resulting in cellular apoptosis and ECM remodelling. We also provide evidence that these 
effects of Hcy were mediated via Akt/FOXO1 signalling pathway, and that H2S mitigates Akt 
/ FOXO1 to exert its protective effect in HHcy condition.   
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Table 1: Primers sequence, melting temperature (Tm), and accession number / 
reference. F, forward; R, reverse.    
 
Primers Sequence Tm (ºC) Accession number/ 
Reference 
MMP-2 F :  5’CACCTACACCAAGAACTTCCGA3’ 
R:  5’ACCAGTGTCAGTATCAGCATCG3’ 
57.1 NM_008610 
MMP-9 F: 5’CACACGACATCTTCCAGTACCA3’ 
R: 5’TCATTTTGGAAACTCACACGCC3’ 
57 NM_013599 
 
MMP-14 F: 5’GGATGGACACAGAGAACTTCGT3’ 
R: 5’GTGACCCTGACTTGCTTCCATA3’ 
57 NM_008608 
GAPDH F: 5’GTCGTGGAGTCTACTGGTGT3’ 
R: 5’TGCTGACAATCTTGAGTGAG3’ 
53.1 [60] 
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Fig. 1A,B. GYY4137 (GYY) and AS1842856 (AS) inhibited Hcy-induced Akt and FOXO1 
signalling in mesangial cells. A) Hcy (50 M, 30 min) deactivated Akt by dephosphorylation, 
and B) activated FOXO1 by dephosphorylation in mesangial cells as measured by Western 
blotting in whole cell lysates. GYY and AS inhibited the effect of Hcy. Bar graphs represent 
ratio of phospho-Akt to total-Akt (pAkt/tAkt (A) and phospho-FOXO1 to total-FOXO1 
(pFOXO1/tFOXO1) (B). Data represents mean ± SEM, n = 9 independent experiments; 
†p < 0.05 vs Control (no treatment); *,#p < 0.05 vs Hcy alone treatment.  
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Fig. 1C,D. Hcy-induced nuclear translocation of FOXO1 was blocked by GYY4137 (GYY) 
and AS1842856 (AS). C) Nuclear extract of mesangial cells treated with Hcy showed higher 
expression of total-FOXO1 in compared to other groups (C), whereas cytosolic extract 
showed reduced total-FOXO1 expression (D) indicating nuclear translocation of FOXO1 by 
Hcy. This indicates Hcy-induced FOXO1 transcription factor activation in mesangial cells. 
GYY and AS has shown to prevent the FOXO1 nuclear translocation and activation. In the 
bar graphs, data represents mean ± SEM, n = 9 independent experiments; †p < 0.05 vs 
control (no treatment), *,#p < 0.05 vs Hcy alone treatment.   
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Fig.1E. Hcy-induced increased FOXO1 activity was normalized by GYY4137 (GYY) or 
AS1842856 (AS) treatment. The mesangial cells were grown in 6-well culture plates and 
treated with Hcy, GYY and / or AS for 24 h. FOXO1 activity levels in the nuclear extracts 
were measured by ELISA based colorimetric kit (ab207204). The bar diagram represents 
relative FOXO1 activity; data mean ± SEM, n = 9 independent experiments; †p < 0.05 vs 
control (no treatment), *,#p < 0.05 vs Hcy alone treatment. 
 
  
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Page | 21 
 
0
0.5
1
1.5
2
C H cy Gyy GYY+H cy A S A S+Hcy
MMP2
MMP9
MMP14
MMP-9
MMP-14
GAPDH
MMP-2
Hcy —  —  — 
GYY — —   — —
AS — — — —  
Hcy —  —  — 
GYY — —   — —
AS — — — —  
0
0.5
1
1.5 MMP-2
MMP-9
MMP-14
†
* #
MMP-9
MMP-14
-actin
}MMP-2ProActive
Fig. 2A,B
A B
†
* #
A
rb
it
ra
ry
 u
n
it
(R
e
sp
e
ct
iv
e
 M
M
P
s 
/ 
G
A
P
D
H
)
A
rb
it
ra
ry
 u
n
it
(R
e
sp
e
ct
iv
e
 M
M
P
s 
/ 

-a
ct
in
)
 
 
Fig. 2. Hcy-induced overexpression of MMP-2, -9 and -14 mRNA (A) and protein (B) was 
normalized in mesangial cells following GYY4137 (GYY) and AS1842856 (AS) treatment. 
The mRNA expression was measured by RT-PCR (A), and immunoblots represent protein 
expression as measured by Western blotting (B). Bar graphs represent densitometric 
analyses of mRNA and protein expression normalized with GAPDH and ß-actin, 
respectively. Values are mean ± SEM, n = 9 independent experiments. †p < 0.05 vs. no 
treatment (control) and *,# p < 0.05 vs. Hcy alone treatment.   
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Fig. 3. Hcy-induced altered expression of collagen I, IV (Col I, Col IV) and Fibronectin (Fbn) 
was normalized in mesangial cells following GYY4137 (GYY) and AS1842856 (AS) 
treatment. Protein expression of Col I, Col IV and Fbn in mesangial cells was measured by 
Western blotting (immunoblots). Bar graph represents densitometric analyses of Col I, Col IV 
and Fbn protein expression normalized with ß-actin. Values are mean ± SEM, n = 9 
independent experiments; †p < 0.05 vs. no treatments (Control) and *,#p < 0.05 vs. Hcy 
treatment.   
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Fig. 4A. Hcy-induced increased expression and localization of MMP-14 and Collagen IV (Col 
IV) in mesangial cells was mitigated by GYY4137and AS1842856. Control and treated cells 
were incubated with primary antibodies and counterstained with appropriate secondary 
antibodies. Immunofluorescence images of cell expressing MMP-14 (green) and Col IV (red) 
were captured under fluorescence microscope. Representative images are from n=8 
independent experiments. Original magnification 100X; Scale bar: 20 μm.  
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Fig. 4B. Hcy-induced expression of Fbn1 in mesangial cells was mitigated by GYY4137 
(GYY) and AS1842856 (AS). Control and treated cells were incubated with primary Fbn1 
antibody and counterstained with appropriate secondary antibody. Immunofluorescence 
images of cell expressing Fbn1 were captured under fluorescence microscope. 
Representative images are from n=8 independent experiments. Original magnification 100X; 
Scale bar: 20 μm.  
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Fig. 5A,B. GYY4137 (GYY) and AS1842856 (AS) mitigated apoptotic cell death in high Hcy 
treated mesangial cells. A) Flow cytometric analysis of cell death by using Annexin V-
FITC/PI staining of apoptotic cells (early & late apoptosis).  Mesangial cells were treated with 
Hcy (50 µM, 24 h) in combination with or without GYY and AS. The viable cell populations 
are in the lower left quadrant (Annexin V-/PI-). The cells at the early apoptosis are in the 
lower right quadrant (Annexin V+/PI-), and the ones at the late apoptosis are in the upper 
right quadrant (Annexin V+/PI+). B) Percent apoptotic cells were shown in this bar 
diagram. Values are mean ± SEM, n = 8 independent experiments; ap<0.05 versus control; 
b,c.dp<0.05 versus Hcy treated cells. MK (MK2206), an Akt inhibitor.  
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Fig. 5. C) Florescence microscopic imaging of mesangial cells stained by TUNEL reagent to 
detect apoptotic cells. Bright green cells are apoptotic positive cells (20X).  Arrows indicating 
TUNEL positive cells. Representative images are from n=8 independent experiments. MK 
(MK2206), an Akt inhibitor.   
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Fig. 6A,B. GYY4137 (GYY) and AS1842856 (AS) mitigated caspase-3/7 expression in Hey 
treated cells. (A) Fluorescence images showing Hcy induced caspase-3/7 in mesangial cells.  
Following Hcy, GYY and AS treatments, cells were stained with CellEvent Caspase-3/7 
Green reagent for 15 min. Nucleus was stained with DAPI. Scale bar is 20 µm. Caspase-3/7 
positive cells exhibited bright green fluorescence; whereas, cells negative to caspase-3/7 
exhibited no fluorescence. Arrows are indicating Caspase-3/7 positive cells. Representative 
images are from n=8 independent experiments. (B) Hcy-induced increased expression of 
caspase-3/7, as measured by Western blotting, was mitigated by GYY and AS treatment.  
Bar graph represents densitometric analyses of cleaved caspase-3/7 protein expression, 
which was normalized with ß-actin. Values are mean ± SEM, n = 9 independent 
experiments; †p < 0.05 vs. no treatments (control) and *,#p < 0.05 vs. Hcy treatment. 
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Fig. 7. Increased ROS by Hcy was diminished by either GYY4137 (GYY) or FOXO1 
inhibitor, AS1842856 (AS) treatment in mesangial cells. A) ROS, superoxide was measured 
by DHE fluorescent activity as described in the material and methods. B) Quantification of 
DHE fluorescence measured by image j software. Values are the mean ± SEM; n = 8; 
*p<0.05 versus control; #, †, p<0.05 versus Hcy treated cells.  
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Fig. 8: Hcy-induced altered expression of MMP-2, -9, -14 and Col I, Col IV, Fibronectin (Fbn) 
was normalized by NAC treatment. (A) The protein expression of MMP-2, -9, -14 and Col I, 
Col IV, Fbn in mesangial cells treated with Hcy with or without NAC was measured by 
Western blotting. (B) Bar graphs represent quantitative measurement of protein expression 
normalized with -actin. Values are mean ± SEM, n=9 independent experiments; †p < 0.05 
vs. Control, and *p < 0.05 vs. Hcy alone.  
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Fig. 9. GYY4137 (GYY) and AS1842856 (AS) treatment reduced Hcy-induced mitochondrial 
depolarization and increased intercellular ATP concentration. A) Fluorescence microscopic 
images of cells subjected to JC-1 staining (60X), scale bar 50 μm. Cells were exposed to 
Hcy (50 µM) for 24 h with or without GYY and AS. Red staining indicates polarized 
mitochondria in control, GYY and AS treated cells; green staining indicates depolarized 
mitochondria in Hcy treated cells. B) Bar diagram represents quantification of JC-1 red-to-
green ratio. Values are the mean ± SEM; n = 8 independent experiments. *p<0.05 versus 
control; #,†p<0.05 versus Hcy treatment. C) Hcy induced reduction of intracellular ATP 
concentration was restored by GYY and AS treatment. Values are the mean ± SEM; n = 9 
independent experiments. *p<0.05 versus control; #,†p<0.05 versus Hcy treated cells. 
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Fig. 10. Schematic of overall findings. Hcy dephosphorylates both Akt and FOXO1 causing 
Akt deactivation and FOXO1 activation. These leads to ROS-mediated cellular apoptosis, 
MMPs activation, and fibronectin and collagen deposition. GYY and AS prevents apoptosis 
and Fbn and collagen deposition, and thus ECM remodelling otherwise induced by Hcy.  
resulting in ECM  and fibronectin induction leading to ECM remodelling. GYY and AS 
Inhibition ofΔΨ mito depolarization, mitochondrial membrane depolarization. pAkt, phospho-
Akt; deAct-Akt, deactivated Akt; pFOXO1, phospho-FOXO1; Act-FOXO1, Activated FOXO1.  
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